NEW YORK (GenomeWeb) – Wells Fargo's Equity Research Department today downgraded Foundation Medicine's stock to Market Perform from Outperform, following the company's first ever analyst day on Tuesday.

Wells Fargo also increased its 2016 estimated loss per share for Foundation Medicine to $1.36 from $1.29, and reduced its stock valuation range to $25 to $27 per share from a previous $35 to $40 per share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.